



11 July 2024

ASX Announcement

BCAL Diagnostics Corporate Presentation

Attached please find a Corporate Presentation to given by Jayne Shaw, Executive Chair of BCAL Diagnostics, at the 18th Bioshares Biotech Summit at the Esplanade Hotel in Fremantle, Western Australia on the 13 July 2024.

This announcement and presentation approved for lodgement with the ASX by the Board.

Guy Robertson
Company Secretary



DRIVING A NEW PARADIGM IN BREAST CANCER DIAGNOSTICS



Bioshares Biotech Summit

Jayne Shaw | JULY 2024

IMPORTANT NOTICE AND DISCLAIMER



This presentation (Presentation) has been prepared by BCAL Diagnostics Ltd ABN 51 142 051 223 (BCAL or the Company).

The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this Presentation is subject to change without notice and, subject only to any legal obligation to do so, BCAL does not have any obligation to correct or update the contents of this Presentation.

The Presentation contains certain “forward-looking statements”. The words “forecast”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, “guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice and involve known and unknown risks and certainties and other factors which are beyond the control of BCAL, and its directors and management, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. Recipients are cautioned not to place undue reliance on forward-looking statements. Refer to the risk factors section of this Presentation for some of the key known risks. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation.

The forward-looking statements are based on information available to BCAL as at the date of this Presentation. Circumstances may change and the contents of this Presentation may become outdated as a result. Except as required by law or regulation, none of BCAL, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

No party other than BCAL has authorised or caused the issue, lodgement, submission, dispatch or provision at the end of this Presentation, or takes any responsibility for, or makes or purports to make any statements, representations or undertakings in this Presentation. To the maximum extent permitted by law, BCAL (including its subsidiaries, related bodies corporate, shareholders, affiliates, advisers and agents):

- disclaims all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation;
- disclaims any obligations or undertaking to release any updates or revision to the information in this Presentation to reflect any change in expectations or assumptions; and
- does not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of the information in this Presentation or the likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement.

Not An Offer

This Presentation is not a prospectus, product disclosure document or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and should not be considered as, an offer, solicitation, inducement, recommendation or an invitation to acquire securities in BCAL or any other financial products, and neither this document nor any of its contents will form the basis of any contract or commitment.

This Presentation may not be distributed to any person in any country outside Australia except to the extent permitted under applicable laws. The release, publication or distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice on such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

Not Financial Product Advice

This Presentation is not financial product, investment advice or a recommendation to acquire BCAL securities and has been prepared without taking into account the objectives, financial situation or needs of individuals. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including, but not limited to, the assumptions, uncertainty and contingencies which may affect future operations of BCAL and the impact that different future outcomes may have on BCAL. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. BCAL is not licensed to provide financial product advice in respect of its securities or any other financial products.

COMPANY METRICS



ASX Code

BDX

Share Price
08 July 2024

\$0.145

Shares on Issue

314M

Unlisted Options

4.5M

Cash
30 June 2024¹

\$6.5M

Top 20 Shareholders

52%

Pre 15 July 2024 General Meeting regarding Tranche 2 of capital raise. If all of Tranche 2 is approved, cash increases by \$4.3m and shares on issue increase by 43M.

A LIPID BLOOD TEST WITH AUTOMATED **ANALYSIS**

} A LIPIDOMIC PLATFORM THAT INCORPORATES AI MACHINE LEARNING AND LEVERAGES ROBUST SCIENTIFIC RESEARCH

~\$300

Proposed cost of test to the patient, following independent research and focus group

BREASTEST[®]

AT COLLECTION CENTRE



Blood collection




Whole Blood



Plasma
Erythrocytes


Pre-processing: sample spin, separate and freeze

TRANSIT



Sample preparation:
plasma lipid extraction

AT TESTING LABORATORY



Sample Analysis: Extracts analysed using Liquid Chromatography Mass Spectrometry (LCMS)




Data analysis for breast cancer lipid signatures (presence or absence)

Logistics & processing scaling confirmed



BREASTEST® WILL BE USED AS A SCREENING TOOL



REGULATORY PATHWAY TO COMMERCIALISATION

SEPTEMBER 2024

DECEMBER 2024

NATA is responsible for accrediting laboratories that develop/manufacture In Vitro Diagnostics (IVDs) in-house

Establish:
“Medical Testing Laboratory”
ISO 15189
National Pathology Accreditation Advisory Council (NPAAC)
Per Therapeutic Goods (Medical Device) Regulations 2002

Laboratory
NATA
accreditation
(Sept 24)

Ongoing generation of analytical data to validate BREASTEST®

SENSIBLE Studies

CLINICAL VALIDATION STUDY
Multi-center observational study

BREASTEST®
launch

Commercialise
test and supply
in-house

AUSTRALIAN LAUNCH

Launch of BREASTEST® in Australia late 2024 & first revenues



NSW & VIC

Q3 CY 2024

Leverage existing sample collection sites prioritising those who can convert to commercial partners e.g. Sydney Breast Clinic

Targeting breast cancer Multidisciplinary Teams (MDT) and Primary Care Providers (GP's)

OTHER AUS STATES


Q3 CY 2024

Focus on raising awareness

Q3 CY2024 APPROACH : NSW & VIC focus + raising awareness in other states

- Who: KOLs and Market Access Team
- Matrix style: Including 1:1 meetings, conference presentations, dinners, educational webinars
- Accelerate education & awareness: Breast surgeons, Breast Clinics, GP's radiology and pathology providers, breast care nurses, advocacy groups and govt agencies
- Develop and implement strategic partnerships: Expediate mass market penetration

AUSTRALIAN DISTRIBUTION LANDSCAPE




COMPREHENSIVE EDUCATION PROGRAM



Establish BREASTEST® as effective, best-in-class screening technology for breast cancer

Community	Advocacy	Referral network	GP's	Breast Surgeons	Lab diagnostics network /Pathology groups/Radiology providers
Social media campaigns and influencers Community health seminars Collaborations with women's health organisations	Continued support and collaboration with advocacy groups such as Breast Cancer Network Australia, So Brave, Sydney Breast Cancer Foundation and Pink Hope.	Build a robust referral network by collaborating with top hospitals, clinics, and health centres. Use CRM tools to manage and streamline referrals. Establish a feedback loop with referring physicians to ensure seamless patient care.	Professional seminars and workshops Continuing Medical Education (CME) credits Detailed informational brochures and clinical evidence	Direct presentations at surgical conferences Peer-reviewed journal publications Collaborative case studies and clinical trial results	Patient management software programs for GP's & Specialists such as Medical Director, HCN, Sonic Software, Best Practice, Medtech Evolution

BCAL IS WORKING WITH CLINICIANS FROM LEADING CENTRES **AROUND THE GLOBE**



A pilot study assessing the feasibility of using the BCAL test for early diagnosis of breast cancer in India

- Lakeview Private Hospital
- Dudley Private Hospital
- Westmead Breast Cancer Institute
- Royal North Shore Hospital
- BreastScreen RPAH

FOCUS MARKET SEGMENTS

} FOUR INITIAL KEY TARGET SEGMENTS

1

Adjunct to current standard of care

Phase 1 of launch;

- Working with existing screening partners in private health sectors
- Generate first revenues while continuing to build the databank

2

Dense breast tissue

~40% if women have dense of extremely dense breast tissue;

- Younger women tend to have more dense breast tissue.

3

Those who are not screened

1.5 million people who;

- Self exclude to due a personal preference or prior experience
- Are unable to be screened due to their remote location
- Have breast implants
- Are concerned about radiation

4

Interval testing

- 8/10,000 women will present with a breast cancer between regular 2 yearly screening.

COMMERCIAL PATHWAY

A 3-year roadmap to saving lives underpinned by a reproducible lipidomic platform and a proprietary biobank of growing data


01 Australian launch



02 Scale Nationally



03 Globalise



BCAL – ACCELERATING TOWARDS COMMERCIALISATION OF BREASTEST®



BREASTEST®
a blood test
that detects
breast cancer

- NATA accreditation scheduled for September 2024, a key part of the inhouse IVD regulatory pathway
- *Commercial launch* in Australia in late 2024
- Commercial launch to initially *leverage existing relationship* with sample collection sites, targeting MDT and GPs
- Leverages *AI-driven technology* in BCAL-owned laboratory and operated Biobank, distinguished from competitors by collecting its own samples with strong clinical protocols and governance in place
- Strong and growing IP estate
- Highly experienced leadership team with a strong track record of success, and a network of Key Opinion Leaders (KOLs) to propel market entry

BREASTEST® is *game changing technology* for women in breast cancer screening.



DRIVING A NEW PARADIGM IN BREAST CANCER DIAGNOSTICS

Thank you

Jayne Shaw

Executive Chair

jshaw@bcaldiagnostics.com

Shane Ryan

Chief Executive Officer

sryan@bcaldiagnostics.com

BCAL Diagnostics Limited

ABN 51 142 051 223

Suite 506, Lvl 5,

50 Clarence Street

Sydney NSW 2000

www.bcaldiagnostics.com

APPENDIX

CLINIC ADVISORY BOARD

} Eminent and influential Breast Clinicians form a National Key Opinion Leader & Clinical Excellence Forum to enhance trust, provide advice and inform the BCAL program



Dr David Speakman



Prof Bruce Mann



Dr Corinne Ooi



A/Prof. James French



Prof. Elisabeth Elder



A/Prof. Cindy Mak



Dr Samriti Sood



A/Prof. Gillian Lamoury



Dr Sally Baron-Hay



Dr Mary Rickard OAM

HIGHLY EXPERIENCED BOARD AND MANAGEMENT



Jayne Shaw
Executive Chair

Successful businesswoman, entrepreneur and co-founder. Previously co-founder and owner of the Sydney Breast Clinic.



Hon Ron Phillips AO
Non-executive Director

Health policy expert, previously Minister for Health in NSW Parliament and co-founder and owner of the Sydney Breast Clinic.



Mark Burrows AO
Independent
Non-executive director

An advocate for early diagnosis of breast cancer and other cancers. International banking expert and has held positions of Chairman and NED of major ASX listed corporations.



Jonathan Trollip
Independent
Non-executive Director

International businessman and lawyer. Many years of experience as NED of large ASX-listed companies.



Dr. John Hurrell PhD
Independent
Non-Executive Director and Consultant

More than 35 years' experience in life sciences & healthcare. Has developed & successfully commercialised multiple products & services as well as managing start up/early-stage companies.



Dr David Darling
Non-Executive Director

David Darling, former CEO of Pacific Edge, brings vast commercial expertise to BCAL with a genetics background and 30+ years experience.



Shane Ryan MBA
Chief Executive Officer

Shane Ryan, former Global SVP of Strategy & Innovation at GenesisCare, with 20+ years in oncology, specializes in breast cancer, excelling in patient care, research, and innovative service models.



Dr Amani Batarseh PhD
Chief Scientific Officer

PhD from Georgetown University, Washington, DC Completed post-doctoral studies at Harvard, McGill and Wollongong Universities. Expert in molecular biology lipidomics and mass spectrometry.



Guy Robertson
Chief Financial Officer &
Company Secretary

A Finance Director/Chief Financial Officer for a number of companies within the Jardine Matheson Group over a period of 16 years. Provides CFO and company secretary consulting services to many large corporations and SMEs.



Alison Cook (Mew), MSc
Quality and Regulatory
Advisor

Management and leadership experience of more than 30 years across the biopharmaceutical, diagnostic and health service sectors. Spent 13 years in senior executive roles at CSL Limited. Consulted widely across the life sciences industry.



Kathy Koskiris BSc. MBA.
Director, Clinical Laboratory
Services

More than 20 years' experience in building and managing clinical laboratories under TGA and US CLIA regulations. Managed CLIA certification for multiple new products, CLEP certification and NATA Accreditation with ISO15189 & NPAAC standards.



Dr Simon Preston PhD
Director Clinical Research

15 years of Research and Development experience across academic and industry roles. Extensive clinical and preclinical experience in both pharmaceutical and diagnostics.

BREASTEST[®] HAS A STRONG AND GROWING **INTELLECTUAL PROPERTY ESTATES**

Title	IP covered	Jurisdiction	Status	Patent number	Priority date	Expected expiry date
Methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	AU (AU1)	Granted	AU Pat. No. 2011270968	23 June 2010	22 June 2031
Methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	AU (AU2)	Granted, Divisional filing	AU Pat. No. 2016213855	23 June 2010	22 June 2031
Methods related to cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	US (US2)	Pending, Divisional filing	US 17/305,824	23 June 2010	22 June 2031
Methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	CA (CA1)	Pending	CA 2,803,865	23 June 2010	22 June 2031
Methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	EP (EP1)	Granted	EP Pat. No. EP 2585833	23 June 2010	22 June 2031
Use of fatty acids in methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	EP (EP2)	Granted	EP Pat. No. 3206034	23 June 2010	22 June 2031
Methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	EP (EP4)	Pending	EP 21200018.6	23 June 2010	22 June 2031
Methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	HK (HK1)	Granted	HK Pat. No. 1180764	23 June 2010	22 June 2031
Methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	HK (HK2)	Pending	HK 42022052007.6	23 June 2010	22 June 2031
Methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	JP (JP1)	Granted	JP Patent No. 5944385	23 June 2010	22 June 2031
Methods for detecting cancer*	Use of plasma lipids as a diagnostic method to detect breast and lung cancer	JP (JP2)	Granted	JP Patent No. 6092302	23 June 2010	22 June 2031
Diagnostic signature	Use of plasma lipids as a diagnostic method to detect breast cancer in combination with machine learning algorithms	PCT stage	Pending	AU2023/050389	10 May 2022	10 May 2043
Diagnostic signature	Use of plasma lipids as a diagnostic method to detect breast cancer in combination with machine learning algorithms	AU Provisional	Provisional	2023903491	31 Octo 2023	N/A

*Licensed from University of Louisville Research Foundation Inc. European (EP) jurisdictions covered: DE, GB, FR, IT, NL, ES.

FINANCIAL MODEL AND ASSUMPTIONS

} A showcase for the Australian roll-out of BCAL's BREASTEST® highlighting cashflow in CY2025 at commencement of modelling, with significant market penetration



Market Size captured through a phased roll-out plan: 16,000 – 30,000 tests in yr 1, ramping on a yearly basis thereafter



Laboratory capacity will be up to 40,000 tests in year one.
80 patient samples per run, 6 runs per week per Mass spec machine, aiming for each MS being operational 48 weeks per year



Costing, capex and maintenance are based on professional experience across specimen logistics and collection and processing costs and lab consumables, capital items such as Mass Spec machines and required replacements; personnel costs based on a per Mass Spec assumption